1	
ו ר	IIILE PAGE
Ζ	
3	Full Title:
4	Proteomic profiling of the large vessel vasculitis spectrum identifies shared signatures
5	of innate immune activation and stromal remodelling
c	
0	Shart Titla
/ 0	Short The.
0	Proteomic proming in large vessel vascultus
9 10	
10	Authors: Debert T. Maurhan ¹² * Frin MacDanald Dunlan ^{1*} Juhna Jaman Dashid ³ Jawisa
12	Sorensen ^{3,4} , Natalie Chaddock ³ , Shauna Masters ⁵ , Andrew Porter ² , Marta Peverelli ² , Charis
13	Pericleous ² , Andrew Hutchings ⁶ , James Robinson ³ , Tarvn Youngstein ² , Raashid A, Lugmani ⁵ ,
14	Justin C Mason ² ^{††} Ann W Morgan ^{3,4} [†] James F Peters ¹ [†]
15	
16	1. Department of Immunology and inflammation. Imperial College London, UK
17	2 National Heart and Lung Institute. Imperial College London, UK
18	3. Leeds Institute of Cardiovascular and Metabolic Medicine. University of Leeds. Leeds. UK
19	4 NIHR Leeds Biomedical Research Centre Leeds Teaching Hospitals NHS Trust Leeds
20	UK.
21	5. Nuffield Department of Orthopaedics. Rheumatology and Musculoskeletal Science
22	(NDORMs), University of Oxford, Oxford, UK
23	6. Department of Health Services Research and Policy, London School of Hygiene & Tropical
24	Medicine. UK
25	
26	*joint first authors, ± joint senior authors, + deceased
27	
28	Correspondence to:
29	r.maughan@imperial.ac.uk, a.w.morgan@leeds.ac.uk, or j.peters@imperial.ac.uk
30	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract 31

32

33 Takayasu arteritis (TAK) and giant cell arteritis (GCA) are the primary forms of large vessel 34 vasculitis (LVV) and can result in serious cardiovascular morbidity. Improved understanding 35 of the molecular basis of these diseases is required to develop novel biomarkers and targeted 36 treatments. Moreover, it is unclear whether shared or distinct pathogenic processes underpin 37 the LVV spectrum. To address this, we performed plasma proteomic profiling, quantifying 184 38 plasma proteins using Olink immunoassays in two independent cohorts totalling 405 39 individuals. In Cohort 1, comparison of patients with TAK (N=96) and large vessel-GCA (LV-GCA) (N=35) versus healthy controls (HCs) (N=35) revealed 52 and 72 significant differentially 40 41 abundant proteins, respectively. Correlation with disease activity status identified novel TAK 42 and LV-GCA disease activity markers. Cohort 2 consisted of patients presenting acutely with possible cranial GCA (C-GCA); C-GCA was subsequently confirmed (n=150) or excluded 43 44 (n=89). 31 proteins were associated with C-GCA. Analyses stratified by temporal artery biopsy 45 results revealed enrichment of the proteomic signal in biopsy-proven GCA, suggesting the 46 presence of distinct endotypes within C-GCA. Cross-disease comparison revealed that active 47 TAK, LV-GCA and biopsy-proven C-GCA had highly similar plasma proteomic profiles. 48 Twenty-six proteomic associations were shared across all three groups including IL6. 49 monocyte/macrophage related proteins (CCL5, CCL7, CSF1), tissue remodelling proteins (VEGFA, TIMP1, TNC) and proteins not previously linked to LVV (TNFSF14, IL7R). We also 50 51 observed disease-specific associations including increased CXCL9 in LV-GCA and C-GCA 52 but not in TAK and decreases in the extracellular matrix protein COMP in TAK but not in LV-53 GCA or C-GCA. Evaluation of publicly available transcriptomic data from LV-GCA aortic tissue 54 revealed that 47 of the 112 proteins significantly altered in \geq 1 LVV type had significantly altered mRNA expression in LVV aortic tissue. Similarities in LVV proteomic profiles suggest shared 55 56 pathobiology involving innate immunity, particularly monocyte/macrophages, lymphocyte 57 homeostasis and tissue remodelling processes. Our results highlight a signature of immune-58 stromal cross talk in LVV and identify potential novel therapeutic targets in this axis (e.g. TNFSF14). The correspondence of plasma signatures to tissue phenotype highlights the 59 60 potential for non-invasive monitoring of arterial inflammation and injury.

Introduction 62

63

64 Takayasu arteritis (TAK) and giant cell arteritis (GCA), the most common forms of large-vessel 65 vasculitis (LVV) in adults, are characterised by granulomatous arterial inflammation. 66 Progressive damage to arterial walls typically results in stenotic remodelling with consequent 67 tissue ischaemia and manifestations such as sight loss, stroke, myocardial infarction and limb 68 claudication¹. Despite phenotypic similarities, TAK and GCA have different demographics, 69 particularly age of onset, and, to a lesser extent, they affect different arterial territories. TAK 70 affects the aorta and its major branches, while classically GCA has been described as 71 involving the cranial arteries (C-GCA) such as the temporal artery. However, following 72 advances in non-invasive vascular imaging techniques, it became clear that the aorta and 73 other large vessels are frequently affected in GCA, and some patients have a large vessel-74 type presentation (LV-GCA) with non-specific constitutional symptoms and/or limb claudication similar to TAK^{2,3}. Frequent large-vessel involvement in GCA and similar 75 76 histopathological changes has led to debate regarding whether TAK and GCA represent varying manifestations of the same disease^{4,5}. This guestion has important implications for 77 78 drug development and clinical trial design. However, such comparisons are currently limited 79 by an incomplete understanding of the pathogenic underpinnings of these diseases and a lack 80 of comparative molecular data across LVV phenotypes.

81

82 There are several important challenges in the clinical management of TAK and GCA. Both 83 initial diagnosis and recognition of relapse may be delayed and are made more difficult by a lack of effective biomarkers⁶. Blood tests such as C-reactive protein (CRP) lack specificity 84 85 while vascular imaging can be insensitive, particularly in glucocorticoid-treated patients, and impractical for frequent serial monitoring^{7,8}. In the era before widespread access to ultrasound 86 87 scans, the diagnosis of C-GCA was confirmed by performing a temporal artery biopsy. While 88 considered the "gold standard" diagnostic test, the presence of skip lesions may lead to false 89 negative results. A negative biopsy therefore does not exclude the diagnosis of GCA. Progress 90 in the treatment of LVV, particularly the development of targeted biologic therapy, lags behind 91 that of other rheumatic diseases. Accordingly, there is overreliance on long-term glucocorticoids to maintain disease control with resulting iatrogenic harm^{9,10}. Thus, there is a 92 93 need for better biomarkers and novel therapeutics to improve patient outcomes.

94

Proteomic profiling has the potential to address these challenges¹¹. Proteins are the effector 95 96 molecules of most biological functions and the targets of most drugs. Given the proximity of 97 arterial tissue to the circulation, blood-based proteomics is likely to be informative in LVV.

98 Specifically, we hypothesised that the levels of inflammation- and cardiovascular-related 99 proteins will provide a read-out of disease activity and arterial pathobiology in LVV patients 100 and enable evaluation of molecular similarities and differences between GCA and TAK. To 101 this end, we performed proteomic profiling of 184 circulating proteins in two independent 102 cohorts that included 281 patients with TAK, LV-GCA or C-GCA. We identify protein signatures 103 associated with each LVV type and with disease activity. Cross-disease comparison revealed 104 a striking similarity between the proteomic profiles of active LVV types. Our data indicate the 105 shared dysregulation of innate immune and tissue remodelling pathways and highlight the 106 potential for therapeutics targeting immune-stromal cross-talk.

107

108 **Results**

109

To identify proteins associated with LVV and to evaluate the presence of shared or distinct molecular signatures across TAK, LV-GCA and C-GCA, we measured plasma levels of 184 inflammation- and cardiovascular-related proteins (**Table S1**) in two independent cohorts using the Olink Target antibody-based proximity extension assay (PEA) (**Figure 1**). To provide a standardised nomenclature, we report proteins using the non-italicised HUGO gene symbol of the encoding gene.

116

117 Shared plasma proteomic profiles in TAK and LV-GCA

118 Cohort 1 included 96 TAK patients, 35 LV-GCA patients and 35 healthy controls (HCs) (Table 119 1). Patient characteristics were typical for TAK and LV-GCA with regards to age and sex, with 120 younger onset and greater female:male ratio in TAK. HCs were well matched in terms of 121 demographics to the TAK patients. LV-GCA patients were older and had a higher proportion 122 of individuals of White European ancestry. The patient samples analysed encompassed a 123 broad range of disease activit.0y, disease duration and treatment status, particularly in TAK 124 where sample size was greater. Patients with active disease tended to have shorter disease 125 durations and were receiving higher glucocorticoid doses, as might be expected (Table S2). 126 In Cohort 1, 158 proteins (86%) passed quality control (QC) parameters (Methods) and were 127 available for analysis.

128

129 Comparison of proteomic profiles between TAK patients and HCs identified 52 differentially

abundant proteins (DAP), with 42 upregulated and 10 downregulated (Figure 2A, Table S3).

131 Cross-referencing of our results to those of a previous study¹² which used a different proteomic

132 platform demonstrated that many of our proteomic associations were novel (**Figure S1**, **Table**

133 S3). We next compared LV-GCA to HCs, revealing 72 DAP, with 60 increased and 12

134 decreased (Figure 2B, Table S4). The proteomic changes in TAK and LV-GCA in comparison 135 to HCs were highly similar; 40 proteins were significantly altered in both diseases and 85% of 136 all proteins had directionally concordant changes compared to HCs (Figure 2C). Proteomic similarity of TAK and LV-GCA was also reflected in principal component analysis (PCA), with 137 138 TAK and LV-GCA clustering together and separated from HCs (Figure S2A).

139

140 As expected, many upregulated proteins in TAK and LV-GCA indicated immune activation including cytokines, chemokines, and growth factors (Figure S2B). Plasma IL6, the pleiotropic 141 cytokine of known importance to LVV pathogenesis¹³, was significantly upregulated in both 142 TAK and LV-GCA (Figure 2E), together with liver-derived inflammatory proteins such as SAA4 143 144 and FCN2. Prominent innate immune involvement in both TAK and LV-GCA was indicated by 145 levels of neutrophil-derived proteins (S100A12, LCN2, DEFA1) and increased 146 monocyte/macrophage activation and chemotactic factors (CSF1, CCL3, CCL5, CCL7, 147 CCL14). Plasma levels of TNF (tumour necrosis factor), IL12B and IFNG were not significantly 148 altered despite previous links to TAK pathogenesis¹⁴. In contrast, we observed large increases 149 in OSM (oncostatin M) and TNFSF14 (LIGHT), cytokines not previously associated with LVV 150 (Figure 2E). In addition to the dysregulation of immune-related proteins, we observed the 151 upregulation of proteins with functions related to the extracellular matrix (TIMP1, MMP1, 152 CST3, TNC), fibrosis (TGFB1) and angiogenesis (VEGFA, HGF, ANG, COL18A1) in both diseases, likely reflecting a signature of arterial injury and remodelling. Six proteins were 153 154 consistently downregulated in both diseases, including IL7R, KIT, TNXB and THBS4 (both 155 extracellular matrix (ECM) related glycoproteins), DPP4 (a glucose metabolism and T-cell 156 activation factor) and CR2 (the complement C3d receptor).

157

158 To evaluate whether there were disease-specific effects, we performed a direct comparison 159 of TAK versus LV-GCA, which revealed 6 significant DAP (Table S5). Visualising the relative 160 abundance of these proteins in each group demonstrated that the dysregulation of these proteins appeared to be LV-GCA specific (Figure S3A). For example, in LV-GCA, but not 161 162 TAK, CXCL9, CCL11 and CA3 levels were elevated compared to HCs. Similarly, CR2 and 163 TNFSF11 (or RANKL) were significantly reduced in LV-GCA but not in TAK. Changes specific 164 to TAK were less prominent, with no proteins that had significant changes in TAK versus both 165 HCs and LV-GCA. However, we observed that FGF23 and IL17A were significantly increased 166 in TAK compared to HCs but were not significantly increased in LV-GCA versus HC (Figure 167 S3B).

medRxiv preprint doi: https://doi.org/10.1101/2024.09.06.24313218; this version posted September 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

169 Signatures of active disease in TAK and LV-GCA patients

170 To identify proteins associated with disease activity in TAK and LV-GCA, we next compared 171 the proteomic profile of active and inactive patients within each disease. In TAK, 16 proteins were significantly altered in active disease, with 11 upregulated and 5 downregulated (Figure 172 173 **3A**, **Table S6**). Upregulated proteins included neutrophil-related factors (S100A12, CXCL5) 174 CXCL1), liver-derived proteins (SAA4, CFHR5), ECM components (TNC, NID1, CRTAC1, 175 COMP) and angiogenic factors (VEGFA, ANG), indicating innate immune activation and 176 vascular remodelling (Figure 3B). To corroborate the results of the active versus inactive 177 patient analysis and identify proteins whose levels vary with the degree of disease activity, we tested for association with the numerical ITAS2010 disease activity score¹⁵. 8 of the 158 178 179 proteins measured were significantly correlated (adjusted P<0.05) with the ITAS2010 score 180 (Figure S4A & C), and 7 of these 8 were differentially abundant in the active versus inactive 181 analysis.

182

183 Assessment of disease activity in TAK is currently based on the evaluation of clinical features, 184 imaging, and clinical laboratory measures of inflammation, particularly CRP levels. However, 185 CRP lacks both sensitivity and specificity for active TAK⁷. We found that 6 proteins (NID1, 186 TNC, S100A12, CD274 (sPD-L1), DEFA1 and DPP4) were more strongly correlated with 187 ITAS2010 than CRP. In addition, for the 20 active TAK patients who had normal CRP levels (<5mg/L), 12 (60%) had abnormal levels (defined as greater than the mean + 3 standard 188 189 deviations of HCs) in one or more of the ITAS2010-associated proteins, indicating their 190 potential added value as markers of disease activity (Figure S4D).

191

In LV-GCA, 18 proteins were significantly associated with active disease, with 17 increased 192 193 and 1 decreased (Figure 3A, Table S7). Although two proteins (CFHR5 and VEGFA) were 194 increased in active disease in both LV-GCA and TAK, the LV-GCA activity signature was 195 largely distinct to that of TAK (Figure 3A). A more prominent acute phase response was 196 evident in active LV-GCA compared to TAK with large increases in IL6 and multiple liver-197 derived inflammatory proteins (MBL2, ST6GAL1, C2) (Figure 3D). There were also 198 differences in the chemokines and other immunoregulatory proteins affected; CXCL5 and 199 CXCL1 levels were not significantly changed in active LV-GCA (Figure 3E) but there were 200 increases in the monocyte-attracting chemokines (CCL7, CCL14, CCL23) and the T-cell 201 recruitment and activation factors (CCL18, GNLY, TIMD4). Lastly, there were activity-202 associated increases in remodelling associated proteins TIMP1, COL18A1 and NRP1 in LV-203 GCA but not TAK.

205 To determine whether proteomic differences persist despite clinical remission, we compared 206 inactive TAK and LV-GCA patients to HC participants. This analysis identified 22 and 61 DAP 207 in inactive TAK and LV-GCA, respectively, with 18 common to both diseases (Figure S5A-C, 208 Tables S8 & S9). Examples of proteins which remained elevated in inactive disease include 209 OSM, S100A12, TNFSF14 and AXIN1 (Figure S5D). Importantly, these proteins remained 210 chronically elevated regardless of disease duration (Figure S5E), even in TAK patients who 211 had withdrawn all treatment following durable remission (Figure S5D; median time off 212 treatment 2 years [inter-quartile range, IQR: 1.5-5.1]). Thus, our data indicate that a proportion

of the proteomic changes observed in TAK and LV-GCA patients represent persistent

214 215

213

216 Biopsy proven C-GCA has a distinct proteomic endotype

molecular derangements which do not normalise with clinical remission.

We next performed proteomic profiling of an independent cohort (Cohort 2) of 239 patients 217 presenting acutely with possible C-GCA, recruited to the TABUL study¹⁶. Blood samples were 218 taken rapidly following initiation of high dose glucocorticoids; median treatment duration was 219 2 [IQR: 1-4] days. All patients underwent both temporal artery biopsy (TAB) and ultrasound 220 sonography (USS) and a diagnosis of C-GCA was subsequently confirmed or excluded (Not 221 C-GCA). Patient characteristics were typical for suspected C-GCA, with the majority of cases 222 being over 60 years old (87.4%) and a predominance towards female sex and White European 223 ancestry (Table 2). 56 (37.3%) of patients diagnosed with C-GCA had a positive TAB, 78 224 (52%) had an abnormal USS and 53 (35.3%) were negative for both TAB and USS with the 225 diagnosis made on the basis of clinical features. Compared to Not C-GCA patients, C-GCA 226 patients were slightly older (median age 4 years greater) and had higher ESR, CRP and 227 platelet levels (Table 2). Proteomic profiling was performed using the same Olink platform. 228 167 proteins (91%) passed QC parameters and data from a minimum of 225 patients were 229 available for analysis (Methods). 230

231

232 Proteomic comparison of C-GCA patients (n=150) to Not C-GCA cases (n=89) revealed 31 233 DAP (Figure 4A, Table S10). Further investigation revealed heterogeneity of these protein 234 profiles within C-GCA patients and that differences compared to Not C-GCA cases were 235 mostly driven by the TAB positive (TAB+) C-GCA patient subset (Supplementary Methods. 236 Figure S6). In analyses stratified by TAB result, comparison of TAB+ C-GCA (n=56) to Not C-237 GCA identified 62 DAP (Figure 4B, Table S11), while only 1 DAP was identified in the TAB 238 negative (TAB-) C-GCA (n=89) versus Not C-GCA comparison (Table S12). The increase in 239 significant associations when limiting to biopsy-proven cases despite reduction in sample size and hence statistical power indicates that TAB+ C-GCA is enriched for proteomic signal, and 240

241 that the TAB- group were diluting this signal in the analysis of all C-CGA versus Not C-GCA. 242 Comparison of the estimated log₂ fold changes (log₂FC) and protein abundances from the 243 TAB+ and TAB- stratified analyses confirmed larger magnitudes of effect in the former (Figure 244 4D & 4F). We additionally found that TAB+ C-GCA patients had higher levels of CRP, ESR, 245 platelets and presence of polymyalgic symptoms compared to TAB- C-GCA patients (Figure 246 4C & Table S13). Moreover, PCA of all proteins assayed indicated separation of TAB+ from 247 TAB- C-GCA patients (Figure S6C). Together, these findings indicate that C-GCA can be 248 stratified into biologically and clinically distinct subsets by TAB result.

249

250 Further exploration of TAB- patients with hierarchical clustering revealed that while the large 251 majority did not share the TAB+ associated signature, 18 TAB- patients were similar to TAB+ patients (Figure S7). However, this pattern had no significant association with demographic 252 253 or clinical parameters. Relatedly, the comparison of C-GCA TAB- patients who had abnormal 254 USS (N=36) to Not C-GCA cases did not identify any significant proteins. Together, these 255 results suggest that TAB rather than USS positivity more closely reflects the proteomic 256 phenotype.

257

258 The 62 proteins associated with TAB+ C-GCA patients suggest both innate and adaptive 259 immune activation with dysregulation of cytokines, growth factors, chemokines and other immune-related proteins (**Figure 4E**). In a previous proteomic study¹⁷, five of these proteins 260 261 were identified as significantly altered in C-GCA (Figure S8 & Table S11). Similar to TAK and 262 LV-GCA, many proteins involved in innate immune function were upregulated including acute 263 phase response mediators (IL6, MBL2, SAA4, CFHR5, ST6GAL1) and factors involved in 264 neutrophil and monocyte migration and activation (CXCL1, CCL14, CCL7, S100A12, CSF1). 265 Several chemokines involved in T- and B-cell recruitment were also increased (CXCL9, 266 CXCL10, CXCL11, CCL18) together with altered levels of lymphocyte survival and 267 proliferation factors (increased IL7, decreased: IL7R, KITLG, TNFSF11). In addition, increases 268 in ECM (MMP1, TIMP1, TNC, LTBP2), fibrosis (TGFB1) and angiogenesis-related proteins 269 (VEGFA, HGF, NRP1) were indicative of vascular remodelling. The downregulated proteins 270 with the lowest p-values were SERPINA5 and DPP4 (Figure 4F). In secondary analyses, we 271 did not identify any proteins that were significantly associated with cranial ischaemic 272 complications or polymyalgic symptoms within C-GCA patients when analysed both as a single group and when separated by TAB result. 273

275 Correlated proteomic changes in active TAK, LV-GCA and biopsy-proven C-GCA with

276 IL6 and VEGFA identified as key hub proteins

277 We next explored similarities and differences in the plasma proteomic signatures associated 278 with each form of LVV. We considered the possibility that our results might be impacted by 279 differences in study design. In Cohort 2, C-GCA patients were sampled with active disease at 280 the time of diagnosis, whereas in Cohort 1, patients were sampled during both active and 281 inactive disease over a range of disease durations. To mitigate against this, we re-analysed 282 Cohort 1 restricting case samples to active disease only. These analyses revealed 68 and 69 283 differentially abundant proteins for active TAK versus HCs and active LV-GCA versus HCs 284 respectively, of which the majority had also been significantly altered in the corresponding 285 previous analyses using all cases (80.9% and 81.6% respectively, Tables S14 & S15). We 286 then compared the results of these TAK and LV-GCA analyses to the proteomic associations 287 identified in the TAB+ C-GCA versus Not C-GCA comparison in Cohort 2.

288

289 112 DAP were identified in one or more LVV type (subsequently referred to as LVV-associated 290 proteins, Figure 5A, Table S16). Directional changes were highly similar with 74 (66.1%) 291 having concordant changes (Figure 5B) and significant correlation between both TAK and 292 LV-GCA profiles with that of TAB+ C-GCA (Pearson r 0.49 and r 0.69, respectively, both 293 P<0.0001). Twenty-six proteins (23.2%) were dysregulated in all three diseases and 33 294 proteins (29.5%) were dysregulated in two. Of the 26 shared DAP, all had directionally 295 concordant changes, including 20 upregulated and 6 downregulated proteins. We define these 296 26 proteins as the 'pan-LVV signature' (Table S16). Upregulated proteins included IL6, acute 297 phase proteins (SAA4, CFHR5, ST6GAL1), monocyte and neutrophil factors (S100A12, 298 CSF1), monocyte and lymphocyte chemokines (CCL5, CCL7, CCL3, CCL18, CCL23) and 299 TNFSF14. Also increased were proteins related to arterial remodelling including VEGFA, 300 HGF. MMP1. TIMP1 and the ECM glycoprotein Tenascin C (TNC). Decreases included IL7R. 301 KIT and KITLG, each involved in lymphocyte differentiation and proliferation, DPP4, CR2 and 302 TNXB (another ECM tenascin).

303

Using the GTEx tissue transcriptome database¹⁸, we explored the global tissue expression 304 305 profile of each LVV-associated protein, defining enhanced expression as >4 fold higher than average tissue level as per Human Protein Atlas methodology¹⁹. 83 (74.1%) had enhanced 306 307 expression in ≥ 1 tissue. The most represented tissues were liver, spleen and whole blood 308 (Figure S9). 11 proteins had enhanced arterial expression including TNC, TIMP1, COL18A1 309 and TNFRSF11B (OPG), thereby indicating the possibility of blood-based measurement of 310 arterial biomarkers in LVV.

312 To infer relationships between proteins, we constructed two networks using the 74 proteins 313 with concordant changes using i) annotated protein-protein interactions using String-db²⁰ 314 (Figure 5C) and ii) co-expression (Pearson *r*≥0.6) (Figure 5D). The network of annotated 315 interactions identified IL6 and IL10 as the central hubs with connections to proteins with 316 distinct functions including chemotaxis (e.g. CCL5, CCL3), angiogenesis (e.g. VEGFA, HGF) 317 and tissue remodelling (e.g. MMP1, TIMP1, TGFB1). In the network constructed using protein 318 co-expression data, TIMP1 and VEGFA displayed even greater connectivity, appearing as 319 central nodes with edges connecting both to other remodelling-related proteins (e.g. 320 COL18A1, NRP1) and multiple immune-associated proteins (e.g. CSF1, TNFSF14, CCL14). 321 These networks indicate the coordinated regulation of immune and vascular remodelling 322 processes, suggesting immune-stromal cross-talk in LVV.

323

324 The most prominent inter-disease differences diseases were between TAK and LV-GCA 325 profiles compared to TAB+ C-GCA (Figure 5A). In particular, the large increases in EIF4EBP1 326 and AXIN1 observed in TAK and LV-GCA were not seen in C-GCA. Similarly, increases in the 327 neutrophil proteins DEFA1 and LCN2 were observed exclusively in TAK and LV-GCA (Figure 328 5E). There were also differences between LV-GCA and TAB+ C-GCA profiles compared to 329 TAK which indicate some degree of divergence between diseases. For example, increases in 330 CXCL9 and TIMD4 were seen only in the GCA groups while decreases in the ECM-related 331 proteins COMP and THBS4 were only found in TAK (Figure 5F).

332

333 Plasma proteomic signatures reflect LVV arterial tissue phenotype

334 Plasma proteins arise not only from blood cells but also from a wide range of tissues and 335 organs, including the vasculature which is in direct contact with the blood. We therefore sought 336 to evaluate whether changes in patient plasma (Figure 5A) reflect the phenotype of arterial 337 tissue affected by LVV. Using bulk RNA-seg data from a study which compared surgically 338 resected aortic tissue of LV-GCA to non-inflammatory aortic aneurysms (NI-AA)²¹, we found 339 that for 47 (42%) of the LVV-associated plasma proteins, the corresponding gene was 340 differentially expressed in LVV arterial tissue (Figure 6A, Table S17). Moreover, the log₂FCs 341 of these 47 plasma proteins correlated with the log₂FC of the corresponding gene in LVV 342 tissue versus NI-AA (Figure 6B), and 28 (59.6%) had directionally concordant changes across 343 the transcriptomic analysis of LVV arterial tissue and the plasma proteomic analyses of all the 344 3 LVV types.

345

346 Using the blueprint and GTEx bulk RNA-seq datasets^{18,22}, we explored the cell-type and 347 arterial expression profile of the 47 genes/proteins dysregulated in both plasma and arterial

348 tissue (Figure S10A). Macrophage and neutrophil expressed genes/proteins made up the 349 largest subset (34%); this included CCL7, CSF1, CXCL9 and CDCP1 which were increased 350 in both tissue and plasma (Figure 6C). Genes/proteins expressed by non-immune stromal 351 cells such as TNC, MMP1, TIMP1 and NRP1 were also prominent (Figure 6D). This latter 352 cluster was enriched for genes of high arterial expression (GTEx) and could be useful as 353 markers of arterial remodelling. The remainder were lymphocyte-derived (Figure 6E) or had 354 mixed expression profiles. Of note, despite the significant decreases in plasma protein levels 355 of DPP4, CR2 and IL7R in LVV, expression of the corresponding genes was significantly 356 increased in LVV arterial tissue (Figure S10B), emphasising that there may be discordance 357 of direction of effect in different tissue compartments. Overall, these findings indicate that 358 plasma proteomic signatures can reflect aspects of LVV tissue phenotype and could provide 359 a valuable non-invasive read-out of pathogenic processes occurring in diseased arteries.

360

361 Discussion

362

TAK and GCA are currently classified as separate diseases^{23,24} but some investigators have proposed that they could represent varying manifestations of the same disease spectrum^{4,5}. This debate has largely focused on phenotypic similarities, reflecting patterns of arterial injury³. Genome-wide association studies reveal differences in the genetic risk factors that predispose to TAK or GCA²⁵. However, a key unanswered question is whether the molecular effector pathways acting in these diseases are shared or distinct. This information is critical for the rational selection of new therapeutic strategies that target specific proteins.

370

371 Here, we address this by comparing the plasma proteomic profile of TAK, LV-GCA and C-372 GCA. In 281 patients with LVV, we measured 184 inflammation- and vascular-associated 373 proteins to characterise the plasma proteome of each major LVV type and evaluate changes 374 associated with disease activity states. We found that the proteomic profiles associated with 375 active TAK, LV-GCA and biopsy-proven C-GCA were similar and identified a 26-protein 'pan-376 LVV' signature common to all three groups. This signature primarily included proteins of 377 immunological function, but it also comprised proteins arising from or acting on the stroma. indicative of arterial injury and/or repair. Some of these proteins have well-established roles 378 379 in LVV (e.g. IL6 and VEGFA)^{13,14}, but others have not been previously linked to LVV. 380

The signature reflected prominent innate immune activation, particularly with increases in several proteins related to monocyte and macrophage function. Importantly, co-expression analysis revealed coordinated regulation of such proteins (e.g. CSF1, CCL18, CCL14) with multiple proteins involved in tissue remodelling (e.g. VEGFA, TIMP1 and TGFB1) thereby

highlighting innate immune-stromal crosstalk in LVV. This is consistent with recent reports implicating pro-fibrotic macrophage subsets in the fibrotic and stenotic remodelling of arteries in TAK and GCA, cell types that are less affected by current treatments^{26,27}. These findings underscore the importance of macrophages in TAK and GCA pathogenesis and illustrate the need for markers and therapeutics which target macrophages beyond pro-inflammatory functions alone.

391

392 We also observed evidence for adaptive immune involvement, with changes in lymphocyte-393 related proteins like IL7R and TNFSF14. Plasma IL7R was decreased in all LVV groups, and its ligand IL7 was significantly increased in TAK and C-GCA. IL7 is essential for T-cell 394 395 development and homeostasis whilst soluble (sIL7R) potentiates IL7 activity by enhancing 396 bioavailability²⁸. The pattern observed is similar to findings in ANCA-associated vasculitis and 397 tuberculosis infection but contrasts with rheumatoid arthritis and lupus where sIL7R levels are 398 increased²⁹⁻³¹. As another example, TNFSF14 (LIGHT) was prominently elevated. TNFSF14 399 acts as a T-cell costimulatory factor and triggers T-cell activation and proliferation³². TNFSF14 400 promotes systemic immunopathology, as demonstrated by transgenic animals with 401 constitutive TNFSF14 expression in T-cells³³. Moreover, TNFSF14 can also act on non-402 haematopoietic structural cells including fibroblasts, endothelial and smooth muscle cells to 403 drive tissue fibrosis³⁴. Consistent with this, our co-expression network analysis identified an 404 edge connecting TNFSF14 to VEGFA, a central hub node. Current treatment strategies in 405 LVV are limited to suppression of inflammation and do not target fibrosis directly. Thus, 406 TNSF14 antagonism may be a novel therapeutic approach in LVV that provides dual targeting 407 of both the immune response and the consequent stromal reaction.

408

409 Lastly, the signature included tissue remodelling proteins expressed by immune cells (e.g. 410 VEGFA) or stromal cells (e.g. TNC, TIMP1, MMP1); the latter may represent useful markers 411 of arterial damage independent of inflammation. Increased plasma TNC in LVV is relevant 412 given its enrichment in normal arteries and increased expression in arteries affected by LVV. 413 TNC is an ECM protein primarily expressed by fibroblasts at sites of tissue damage where it 414 supports repair. It gained interest as a candidate marker of vascular injury, but its levels are also elevated in other disease states³⁵. Although its lack of specificity may preclude its use as 415 416 a diagnostic marker, TNC and other ECM proteins could be useful for monitoring arterial injury 417 during follow-up and should be evaluated in longitudinal studies.

418

Despite the overall similarity in LVV proteomic profiles, we identified differences which suggest
some immunological divergence between diseases. For example, the chemokine CXCL9 was
higher in LV-GCA and C-GCA compared to TAK. CXCL9 is produced by macrophages and

422 other cell types in response to interferon-gamma and typically reflects activation of the Th1 423 pathway³⁶. Increased plasma CXCL9 has been shown previously in GCA and is associated with CXCR3+ cell infiltration into diseased arteries³⁷. Previous studies speculated that TAK 424 and GCA differ in the susceptibility of T-cell pathways to glucocorticoids whereby Th1 425 responses persist in GCA and Th17 responses persist in TAK after treatment initiation^{38,39}. 426 427 Our observation that CXCL9 was exclusively increased in GCA while IL17A was exclusively 428 increased in TAK may support this theory.

429

430 Beyond comparing LVV types, this study provided several disease-specific insights. We 431 identified novel markers of active disease in TAK and in LV-GCA. Disease activity assessment 432 is challenging in LVV, where inflammatory markers such as CRP may not correspond to 433 disease activity detected in radiological or histopathological examination^{7,40}. Further 434 exploration within TAK patients identified six proteins more strongly associated with ITAS2010 435 score than CRP, and we show that their use would provide more sensitive detection of active 436 disease. Importantly, we also found that many proteins remained altered in TAK and LV-GCA 437 patients despite remission. OSM and AXIN1 were elevated regardless of activity, disease 438 duration or treatment withdrawal. Activity markers like S100A12 and VEGFA were highest in 439 active disease but remained increased in inactive disease. These findings likely reflect 440 persistent low-grade inflammation and are analogous to the residual molecular signatures 441 previously described in a multi-omic study of remission in rheumatoid arthritis⁴¹. However, 442 whether persistent molecular abnormalities impact clinically important outcomes remains 443 unknown.

444

Our results suggest that biopsy-positive and negative C-GCA are proteomically distinct. There 445 446 are two possibilities that could explain our findings. First, despite a careful clinical phenotyping 447 algorithm which included external expert review, there may be instances of misclassification 448 within the TAB- C-GCA group, such that some patients were erroneously labelled as C-GCA. 449 However, this cannot fully explain our findings since the TAB- C-GCA group included some 450 patients with a positive USS. Alternatively, TAB positivity may reflect the burden of arterial 451 disease. Skip lesions, with discontinuous segments of arterial inflammation, can occur in GCA 452 and so a patient with lower burden of arterial disease is more likely to have a negative biopsy 453 on the small biopsy section of artery sampled. Thus, it is possible that the proteomic read-out 454 may reflect quantitative differences in the extent of arteritis. Our clinical lab data provided 455 additional evidence of differences between TAB+ and TAB- patients, with higher ESR, CRP and platelet count in the former group, in keeping with previous studies^{42–44}. Other clinical 456 differences in TAB+ and TAB- C-GCA have been described, including greater risk of visual 457 458 loss^{44,45} and higher prevalence of PMR in TAB+ patients⁴², although these findings have not

replicated in all case series⁴⁶. Our data support the concept that C-GCA can be stratified by
 biopsy into biologically distinct endotypes, which may have potential implications for future trial
 design and precision medicine strategies.

462

463 Our study had certain limitations. We used a targeted proteomic panel enriched for 464 inflammatory and vascular proteins and thus our ability to compare between LVV groups is 465 limited to the proteins measured. The HCs in Cohort 1 were well-matched to TAK patients but 466 were younger than LV-GCA patients. Differences in study design between Cohort 1 and 467 Cohort 2 mean that proteomic differences between C-GCA and the other LVV groups may be 468 confounded by differences in disease duration and treatment history. In addition, the controls 469 in Cohort 2 ("Not GCA") were individuals who presented with symptoms for which a diagnosis 470 of C-GCA was considered but ultimately excluded, whereas the controls in Cohort 1 were 471 healthy participants with no symptoms. In Cohort 1, there was heterogeneity in treatment, with 472 varying use of steroids and other immunosuppressants which could potentially impact the 473 plasma proteome. However, treatment (particularly glucocorticoid dose) is given in response 474 to disease activity, reflected in the correlation between disease activity scores and 475 prednisolone dose in Cohort 1. Thus attempting to statistically adjust for treatment risks over-476 adjustment^{47,48}. Finally, in the case of membrane-bound proteins that undergo cleavage to 477 produce a soluble form, it is not always clear whether plasma protein measurements are 478 exclusively capturing the latter or also protein from cell membranes (for example, arising from 479 in vivo sources such as exo-/ectosomes or ex vivo processes such as venepuncture or sample 480 processing), complicating interpretation.

481

In conclusion, similarities in the plasma proteomic profiles of active TAK and GCA indicate 482 common effector pathways resulting in inflammatory arterial damage despite differences in 483 484 genetic aetiology. Our integrated analysis of plasma and arterial tissue highlight the role 485 played by macrophages and their protein products in LVV and indicate significant potential for 486 their targeting in novel treatments and biomarkers. Future work should expand the molecular 487 characterisation of the LVV disease spectrum by extending the number of proteins measured 488 via use of complementary proteomic platforms and by concurrent measurement of other -omic 489 layers (e.g. RNA-seg of immune cells). Longitudinal studies characterising the temporal 490 changes in the molecular profile across the disease course will be valuable in delineating acute 491 from chronic changes and allowing intra-individual assessment of putative biomarkers 492 identified here.

493 Main Figures

Cohort 1

Cohort 2



494

495 Figure 1. Study Overview.

496 Schematic overview of study to investigate the plasma proteomic changes associated with each form

497 of large vessel vasculitis in two independent cohorts. Cohort 1: patients with established Takayasu

498 arteritis (TAK) and large vessel giant cell arteritis (LV-GCA) and healthy control (HC) participants.

499 Cohort 2: patients presenting with possible cranial giant cell arteritis who subsequently had diagnosis

500 confirmed (C-GCA) or ruled out (Not C-GCA). Disease-specific proteomic profiles defined by differential

501 abundance analysis were compared. Network-based analysis of LVV-associated proteins and

502 integrated analysis with published tissue and cell-type datasets was also conducted.





503

504 Figure 2. Plasma proteomic changes in TAK and LV-GCA compared to Healthy Control 505 participants

506 Volcano plots showing results of differential protein abundance analyses: A) Takayasu Arteritis patients 507 (TAK, N=96) vs healthy controls (HC, N=35) B) Large Vessel Giant Cell Arteritis (LV-GCA, N=35) vs 508 HC. -Log10(Padi) = -log10 Benjamini-Hochberg adjusted p-value. Red and blue indicate proteins that are 509 significantly ($P_{adi} < 0.05$) upregulated and downregulated, respectively. C) Venn diagram showing the 510 overlap in proteins significantly altered in TAK vs HC compared to LV-GCA vs HC analyses. D) 511 Comparison of log₂ fold changes in all proteins for TAK vs HC and LV-GCA vs HC analyses, diagonal 512 lines represent line of identity and $+/-0.5 \log_2$ fold change. Blue = proteins significant in both analyses; 513 orange = significant only in TAK vs HC; teal = significant only in LV-GCA vs HC; grey = non-significant 514 in both analyses. E) Violin plots showing scaled protein levels (as Z-scores) for example proteins with 515 prominent changes in both TAK and LV-GCA. P_{adj} < 0.05: *, P ≤ 0.01: **, P ≤ 0.001: ***, P ≤ 0.0001: **** 516

medRxiv preprint doi: https://doi.org/10.1101/2024.09.06.24313218; this version posted September 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .



517

Figure 3. Proteins associated with active disease within TAK and LV-GCA patients 518

A) Points indicating log₂ fold changes and standard error (horizontal bars) for proteins that were 519 significantly (adjusted P < 0.05) differentially abundant in the active vs inactive patient analysis for 520 Takayasu Arteritis only (TAK, N=56 vs N=40) (top panel), both diseases (middle panel) and Large 521 Vessel Giant Cell Arteritis only (LV-GCA, N=11 vs N=24) (bottom panel). B) Functional categories of 522 differentially abundant proteins from TAK and LV-GCA activity analyses. Violin plots depict the scaled 523 abundance values (Z-scores) for proteins associated with disease activity in both diseases (C) and for 524 the proteins which had divergent associations with disease activity in TAK and LV-GCA (D & E). P-525 values adjusted using Benjamini-Hochberg method; No symbol: non-significant, adjusted P < 0.05: *, P 526 ≤ 0.01 : **, $P \leq 0.001$: ***. 527



529 Figure 4. Proteomic changes associated with C-GCA are most pronounced in biopsy 530 proven disease

528

531 A) Volcano plots for the differential protein abundance comparisons of Cranial Giant Cell Arteritis (C-532 GCA, N=150) cases vs Not C-GCA cases (N=89) and B) for the comparison of temporal artery biopsy 533 positive C-GCA (C-GCA TAB+, N=56) versus Not C-GCA (N=89). -Log₁₀(P_{adi}) = -log₁₀ Benjamini-534 Hochberg adjusted p-value. Red and blue indicate proteins that are significantly ($P_{adj} < 0.05$) 535 upregulated and downregulated, respectively. C) Boxplot showing comparison of C-reactive protein 536 (CRP), erythrocyte sedimentation rate (ESR) and platelet count between Not C-GCA, C-GCA TAB+ 537 and C-GCA TAB- patients. Median and IQR represented by line and box edges respectively, upper 538 whisker represents the upper quartile plus 1.5 times the IQR, lower whisker represents lower quartile 539 minus 1.5 times IQR. Statistical comparisons made with Kruskal-Wallis and Dunn's post-hoc tests. D) 540 Comparison of log₂ fold changes for differentially abundant proteins in C-GCA TAB+ vs Not C-CGA and 541 C-GCA TAB- vs Not C-GCA. E) Functional categories of differentially abundant proteins in C-GCA TAB+ 542 vs Not C-GCA comparison. F) Violin plots showing scaled protein levels (Z-score) for example proteins





545

Figure 5. Comparison of active TAK, LV-GCA and biopsy-proven C-GCA proteomic 546 547 profiles

548 A) Heatmap showing log₂ fold changes (FC) of the 112 differentially abundant proteins (DAP) identified 549 in active Takayasu Arteritis (TAK) vs healthy control (HC), active Large Vessel Giant Cell Arteritis (LV-550 GCA) vs HC and temporal artery biopsy positive (TAB+) C-GCA vs Not C-GCA comparisons. Left: navy 551 boxes represent proteins with statistically significant changes (Adjusted P < 0.05) in each disease. 552 Right: annotated functional category for each protein. B) Disease to disease comparison of Log₂ FC for

553 112 DAP, diagonal lines represent the line of identity. Network plots of (C), known protein-protein

- 554 interactions and (D), protein-protein co-expression for proteins with concordant changes in each 555 disease (74). Node size corresponds to the number of connections to other nodes. For C, high
- 556 confidence interactions (≥ 0.9) were sourced from STRING²⁰ and for D, protein co-expression was
- 557 defined as a Pearson correlation ≥0.6 in both active TAK/LV-GCA patients and TAB+ C-GCA patients.
- 558 E) Violin plots showing scaled abundance values (Z-scores) for selected proteins associated with active
- 559 TAK and LV-GCA but not C-GCA (F) and those identified as different between active LV-GCA and C-
- 560 GCA vs active TAK. P-values adjusted using Benjamini-Hochberg method; No symbol: non-significant,
- Adjusted *P* < 0.05: *, *P* ≤ 0.01: **, *P* ≤ 0.001: ***, *P* ≤ 0.0001: ****. 561





Figure 6. Correspondence of LVV plasma profile to arterial tissue phenotype 563

562

564 Comparison of plasma proteomic profiles associated with LVV and gene expression changes identified 565 in aortic tissue affected by large vessel vasculitis (LVV)²¹. A) Pie chart showing the proportion of 112 566 LVV-associated plasma proteins (Table S16) that were also differentially expressed (Adjusted P < 0.05) 567 in the comparison of large vessel giant cell arteritis (LV-GCA) related aortic aneurysm (N=8) to non-568 inflammatory aortic aneurysm (NI-AA) by bulk RNA-seg (N=25). B) Comparison of plasma protein and 569 aortic gene expression log₂ fold changes (Log₂FC) for the 47 proteins and corresponding genes that 570 had significant changes in both LVV plasma and aortic tissue, each point represents a gene/protein 571 pair. For proteomics, Log₂FCs represent active Takayasu Arteritis (TAK) vs healthy control (HC), active 572 LV-GCA vs HC and temporal artery biopsy positive cranial-GCA (TAB+ C-GCA) vs Not C-GCA 573 comparisons. For transcriptomics, Log₂FCs represent LV-GCA associated aortitis vs NI-AA. (C-E), Dot 574 plots showing aortic gene expression of genes/proteins DA in both LVV plasma and aortic tissue. Genes 575 proteins typically expressed by macrophages (C), non-haematopoietic stromal cells (D) and 576 lymphocytes (E). Gene expression measured in transcripts per million (TPM), cell-type expression 577 classified using blueprint data (Figure S8). P-values were adjusted using Benjamini-Hochberg method.

578 Tables

579

580 Table 1: TAK and LV-GCA cohorts

	HC	ТАК	LV-GCA
N	35	96	35
Female (%)	31 (88.6)	91 (94.8)	28 (80)
Age (years)	38.2 [30.4, 52.5]	41.6 [30.9, 55.6]	67.2 [61.3, 72.3]
Ethnicity			
White European (%)	21 (60)	55 (57.3)	30 (85.7)
Asian (%)	11 (31.4)	35 (36.5)	4 (11.4)
Other (%)	3 (8.6)	6 (6.3)	1 (2.9)
Time since diagnosis, yrs	-	3.9 [1.1, 10.3]	1.4 [0.5, 3.7]
Active Disease (%)*	-	56 (58.3)	11 (31.4)
CRP >5mg/L (%)	-	42 (43.7)	17 (48.6)
ESR >20mm/hr (%)	-	59 (61.5)	17 (48.6)
Treatment			
No treatment (%)	-	21 (21.9)	6 (17.1)
Time on Treatment	-	2.6 [0.7, 7.4]	1.4 [0.5, 4.1]
Glucocorticoids (%)	-	62 (64.6)	28 (80)
csDMARD (%)	-	57 (59.4)	18 (51.4)
Biologic (%)	-	7 (7.3)	1 (2.8)

581 Data is median [IQR] or N (%) where indicated. *For Takayasu Arteritis patients (TAK), active disease:

582 ITAS2010 score \geq 1 or ITAS.CRP \geq 2; for large vessel giant cell arteritis patients (LV-GCA): NIH score

583 ≥ 2 at the time of sampling. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. Treatment

584 at time of sampling is summarised. csDMARD, conventional synthetic disease modifying anti-rheumatic

585 *drug; Biologic, targeted biologic agent e.g. anti-IL6R monoclonal antibodies or TNF inhibitor.*

Table 2: C-GCA cohort 586

	Not C-GCA	C-GCA
N	89	150
Age	69 [62 <i>,</i> 76]	73.5 [67, 78]
Female (%)	63 (70.8)	108 (72)
White European (%)	88 (98.9)	149 (99.3)
TAB+ (%)*	0 (0)	56 (37.3)
USS Positive (%)	27 (30.3)	78 (52)
Cranial Ischaemic Complications (%)	18 (20.2)	33 (22)
Polymyalgic symptoms (%)	7 (7.9)	18 (12)
ESR, mm/hr⁺	13 [5, 28]	35 [19.5, 58]
CRP, mg/L ⁺	14 [4, 22.5]	30 [12.7, 54]
Platelets, 10 ⁹ /L ⁺	290 [236, 332]	348 [277, 454]
Data is median [IOR] or N (%) where indic	ated *Six nationts did not have	A TAB result available forby

587 Data is median [IQR] or N (%) where indicated. *Six patients did not have TAB result available. /Only

588 partial data available: Not C-GCA N = 81, 55, 89 for ESR, CRP and platelets respectively; C-GCA N =

589 143, 98, 147. TAB, temporal artery biopsy; USS, temporal artery ultrasound sonography; Cranial

590 Ischaemic Complications (as per methods); ESR, erythrocyte sedimentation rate; CRP, C-reactive

591 protein.

592 Methods

593 Cohort 1 study participants

594 Patients with TAK or LV-GCA were recruited from the Hammersmith Hospital (Imperial College 595 Healthcare NHS Trust, UK) between 2013 and 2020. TAK patients fulfilled EULAR/ACR 2022 596 classification criteria²³ and all had typical patterns of arterial involvement in radiological assessments. 597 LV-GCA patients were >50 years at onset with radiological evidence of LVV, as defined previously¹³. 598 Three LV-GCA patients had concurrent temporal artery involvement (confirmed by temporal artery USS 599 and/or TAB). HC participants were recruited locally from hospital and college staff and had no history 600 of inflammatory or cardiovascular disease. Citrate blood samples were centrifuged at 1000G for 10 601 minutes within 4 hours of venepuncture and plasma was stored at -80°C until use. Disease activity was 602 assessed using the Indian Takayasu Clinical Activity Score (ITAS2010) for TAK¹⁵ and the National 603 Institutes of Health (NIH) score for LV-GCA⁴⁰. Active disease was defined as ITAS2010 score \geq 1 or 604 ITAS-CRP \geq 2 for TAK and NIH score \geq 2 for LV-GCA. All inactive cases were retrospectively confirmed 605 to be relapse free for 1 year following sample collection. Patients and HC provided written informed 606 consent, and samples were collected as a sub-collection registered with the Imperial College Healthcare 607 Tissue Bank (licence: 12275; National Research Ethics Service approval 17/WA/0161).

608 Cohort 2 study participants

- The <u>Temporal Artery Biopsy vs UL</u>trasound in Diagnosis of GCA (TABUL) was an international, multicentre, prospective study which compared the sensitivity and specificity of temporal artery ultrasound to biopsy in 381 patients with suspected C-GCA¹⁶ [ClinicalTrials.gov: NCT00974883]. Reference diagnosis of C-GCA or Not C-GCA at 6 months was based on a combination of baseline signs and symptoms, blood tests, TAB, fulfilment of ACR 1990 GCA classification criteria, clinical course during the follow-up period, final consultant diagnoses and verification by an expert review panel, as described previously¹⁶.
- 616 Cranial ischaemic complications were defined as permanent ocular or non-ocular conditions at 617 presentation. Ocular complications: anterior ischaemic optic neuropathy, branch retinal artery 618 occlusion, cilioretinal artery occlusion, cranial nerve palsy (III, IV or V), central retinal artery occlusion, 619 posterior ischaemic optic neuropathy relative afferent pupillary defect; irreversible visual loss; 620 irreversible visual field defect; irreversible ocular motility or irreversible diplopia. Non-ocular cranial 621 complications: scalp necrosis; tongue necrosis; cerebrovascular accident at presentation considered 622 secondary to GCA). Polymyalgic symptoms at presentation are also reported but do not represent a 623 confirmed diagnosis of polymyalgia rheumatica.
- 624 Citrated blood samples collected as soon as feasible after starting glucocorticoid treatment (median 625 [IQR] 2 [1-4]) and were centrifuged at 2500 G for 15 minutes within 1.5 hours of collection and plasma 626 was stored at -80°C until use. Due to funding constraints and biosample availability, we performed Olink 627 proteomic assays on 239 patient samples out of the 381 patients recruited to TABUL. We included all 628 available samples from patients with a diagnosis of C-GCA. We selected a subset of sex and age (+/-629 5 years) matched Not C-GCA cases such that the ratio of C-GCA to Not C-GCA was approximately 2:1. 630 As part of the study design, we selected an equal proportion of cases with cranial ischaemic

631 complications in the C-GCA group as in the Not C-GCA group. Overall study approval was granted by 632 the Berkshire Research Ethics Committee (09/H0505/132) and approved was also granted at local

- 633 participating clinical sites.
- 634

635 Proteomic analysis

636 184 proteins were measured by proximity extension assay using two Olink Target panels, 'Inflammation 637 1' and 'Cardiometabolic' at the Leeds Immunogenomics Facility, University of Leeds. In order to provide 638 a succinct and standardised nomenclature, we report proteins by the symbols of the genes encoding 639 them (see Table S3 for a full list of proteins and associated full names and accession numbers). Cohort 640 1 and 2 samples were processed and analysed independently, but proteomic measurements were 641 performed in the same facility. We designed assay plates such that samples were balanced across 642 plates according to disease grouping and disease activity status, with randomisation to determine well 643 position within plates. Proteomic data were normalised using standard Olink workflows, which includes 644 inter-plate normalisation, to produce measures of relative protein abundance ('NPX') (log₂ scale). For 645 visualisation, we transformed to Z-scores (mean=0, SD=1). Due to a technical fault with a PCR machine 646 during the running of one plate on the Inflammation 1 panel for Cohort 2, it was necessary to re-run this 647 plate as a separate batch. Principal component analysis (PCA) revealed a batch effect, with samples 648 from this plate separated from samples on the other three plates run as part of the first batch. We 649 therefore adjusted for this batch effect for proteins measured on the Inflammation 1 panel in Cohort 2, 650 using batch (a binary variable) as a covariate in linear model based differential abundance analyses. 651 For situations requiring batch-correction outside of differential abundance testing (e.g. visualisation of 652 protein levels using violin plots and heatmaps and network analyses), the residuals from the linear 653 model (in Wilkinson notation) NPX ~ Batch were used to generate batch-corrected protein values. 654 Further PCA of these residuals confirmed that the batch effect had been removed. The residuals were 655 then converted to Z scores prior to visualisation or other downstream analyses. Cardiometabolic panels 656 for Cohort 1 were not affected by this issue and were analysed as a single batch.

657 Proteins with >75% of samples below the lower limit of detection were removed resulting in 158 and 658 167 protein measurements for Cohort 1 and 2, respectively. Sample-level QC was performed using 659 internal assay controls, boxplots of relative protein abundance values and PCA for outlier detection. In 660 Cohort 1, three samples (1 HC and 2 TAK) were excluded from Inflammation panel measurements due 661 to amplification failures. In Cohort 2, fifteen samples (9 C-GCA and 6 Not C-GCA) were excluded from 662 Inflammation panel and 3 (all C-GCA) from the Cardiometabolic panel measurements due to 663 amplification failures and flagged status in internal QC checks. Wherever possible all available data 664 was analysed (e.g. differential abundance analyses) but some analyses (e.g. hierarchical clustering, 665 PCA, multiple linear regression versus clinical parameters) necessitated using only complete data. The 666 final post-QC datasets are provided on figshare: 10.6084/m9.figshare.26928211.

Differential protein abundance was performed using linear models in R. For a given protein, protein
 abundance was regressed on disease status (encoded as 0 or 1). The beta coefficient for the disease
 status term represents the estimated log₂ fold change in the protein level between groups under

medRxiv preprint doi: https://doi.org/10.1101/2024.09.06.24313218; this version posted September 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 670 comparison. For example, for the analysis of TAK versus HCs, the regression model was NPX ~ D,
- 671 where NPX was log₂ protein level (continuous variable) and D was a binary variable, encoded as 0 for
- 672 HC and 1 for TAK. Correction for multiple testing (multiple proteins) was performed using the Benjamini-
- 673 Hochberg method and an adjusted P-value of < 0.05 (i.e. false discovery rate < 5%) was defined as 674 significant.

675 **Protein annotation**

- 676 Olink panel proteins were manually classified as "Cytokine Related", "Growth Factor Related", 677 "Chemokine, Other Immune/Inflammatory related protein", "Extracellular matrix Related" or "Other 678 Function" for the purpose of the annotation of differential abundance results. This was done using a 679 combination of public resources including Gene Ontology terms, pathway and functional databases.
- 680 The full list of proteins and associated classifications is provided in Table S3.

681 **Network analysis**

682 The protein-protein interaction network between differentially abundant proteins was constructed using 683 high confidence interactions (confidence \leq 0.9) sourced from STRING²⁰. No additional filtering of 684 interactions was performed. The protein co-expression network of differentially abundant proteins was 685 created using inter-protein correlation. Node edges were defined as Pearson $r \ge 0.6$. Cohort 1 (TAK 686 and LV-GCA) and Cohort 2 (C-GCA) networks were computed individually and then intersected so that 687 only correlations present in both networks feature in the final network. Both networks were plotted using 688 the igraph package in R⁴⁹.

689 Tissue expression of differentially abundant proteins

690 GTEx bulk RNA-seq tissue expression data was accessed as median transcript per million values per 691 tissue¹⁸. Data pre-processing included: removal of sex-specific organ data (i.e. cervix, breast, vagina, 692 testis, fallopian tubes), removal of purified cell data (e.g. cultured fibroblasts) and where there were 693 multiple sample types per tissue group (e.g. Artery-Coronary or Artery-Aorta) the highest expression 694 value was used for that tissue type. Enhanced tissue expression of differentially abundant proteins was 695 defined as >4 fold higher than the averages expression in other tissues as done previously by the 696 Human Protein Atlas¹⁹.

697 **RNA-seq analysis of LVV arterial tissue**

698 A previous study compared the transcriptomic profile of inflammatory and non-inflammatory aortic 699 aneurysms using bulk RNA-seq²¹. Gene-level count data was accessed and filtered for cases of 700 inflammatory aneurysm associated with GCA (n=8) for comparison with non-inflammatory cases 701 (n=25). Data was normalised, genes with low expression were removed and groups were compared 702 using the standard edgeR package methodology⁵⁰. Differentially expressed (DE) genes were defined 703 using Benjamini Hochberg adjusted P < 0.05. DE genes were then compared with LVV-associated 704 plasma proteins with regards to overlap and Pearson correlation of log₂ fold change in each disease.

705 Other analyses

706 Details of additional analyses are provided in Supplemental Information File.

707 Data availability

708 Individual-level normalised post-QC proteomic data are provided on figshare:
 709 <u>10.6084/m9.figshare.26928211</u>

710

711 Acknowledgments

We thank Prof. Marina Botto and Prof. Matthew Pickering for helpful comments on the manuscript. We thank the patients and healthy volunteers who participated in this study, along with the clinical research teams who recruited patients. We thank Surjeet Singh as the chief study coordinator for TABUL, and Bhaskar Dasgupta as a co-investigator on TABUL who played a leading role in the study recruitment. Prof Mason tragically passed away during the study and we dedicate this paper to his memory.

718 Sources of Funding

719 This study was funded in part by the Medical Research Council (MRC) "Treatment According 720 to Response in Giant cEll arTeritis" (TARGET) Partnership award, Medical Research Foundation (MRF-042-0001-RG-PETE-C0839), Vasculitis UK (V2105), MRC Confidence in 721 722 Concept (Leeds), the NIHR Imperial Biomedical Research Centre (BRC), and the NIHR Leeds 723 BRC. The TABUL study was funded via an NIHR Heath Technology Assessment grant. N.C. 724 was supported by an MRC DiMen award. CP was supported by Versus Arthritis (Career 725 Development Fellowship, 21223) and Imperial College -Wellcome Trust Institutional Strategic 726 Support Fund (ISSF). J.E.P. is supported by a Medical Research Foundation Fellowship 727 (MRF-057-0003-RG-PETE-C0799). A.W.M. is an NIHR Senior Investigator and supported by 728 the NIHR Leeds BRC and was previously supported by the NIHR Leeds MedTech and Invitro 729 Diagnostics Co-operative and MRC TARGET Partnership grant. The views expressed are 730 those of the authors and not necessarily those of the NIHR or the Department of Health and 731 Social Care.

732 Disclosures

733 J.E.P. has received travel and accommodation expenses to speak at Olink-sponsored 734 academic meetings (none in the last 5 years). C.P. is a recipient of a research grant from 735 Galapagos BV; unrelated this study. A.W.M. previously received a research grant from Roche 736 PLC, for unrelated work, and has undertaken consultancy or received honoraria for speaking 737 at educational events on behalf of her institution from AstraZeneca, Roche and Vifor in the 738 last 5 years. R.A.L has served on advisory boards for GSK and Roche; has received 739 assistance to attend meetings from CSL Vifor; has received grants from Roche, Celgene/BMS 740 and CSL Vifor, and has participated in clinical trials for Roche, GSK, Novartis, and InflaRx.

742 Supplemental Material

- 743 Supplementary Information File.docx
- 744 Supplementary Methods
- 745 Figure S1: Comparing TAK findings to those of a previous plasma proteomic study
- 746 Figure S2: TAK and LV-GCA vs HC comparison
- 747 Figure S3: Plasma protein differences between TAK and LV-GCA patients
- 748 Figure S4: Proteins associated with Disease Activity Score in TAK
- 749 Figure S5: Differentially abundant proteins in inactive TAK & LV-GCA
- 750 Figure S6: Proteomic changes in C-GCA are most pronounced in biopsy proven disease
- 751 Figure S7: Comparison of proteomic changes in TAB+ and TAB- C-GCA patients
- Figure S8: Comparing biopsy proven C-GCA findings to those of a previous plasma proteomic
- 753 study
- 754 Figure S9: Tissue expression of LVV-associated plasma proteins
- 755 Figure S10: Cell-type expression profile of proteins/genes identified as dysregulated in both
- 756 LVV plasma and tissue
- 757

758 Supplementary Data File.xlsx

- 759 Table S1: Proteins measured in this study
- 760 Table S2: Characteristics of TAK and LV-GCA patients with inactive and active disease
- 761 Table S3: Differential protein abundance analysis TAK vs HC
- 762 Table S4: Differential protein abundance analysis LV-GCA vs HC
- 763 Table S5: Differential protein abundance analysis TAK vs LV-GCA
- 764 Table S6: Differential protein abundance analysis Active TAK vs Inactive TAK
- 765 Table S7: Differential protein abundance analysis Active LV-GCA vs Inactive LV-GCA
- 766 Table S8: Differential protein abundance analysis Inactive TAK vs HC
- 767 Table S9: Differential protein abundance analysis Inactive LV-GCA vs HC
- 768 Table S10: Differential protein abundance analysis C-GCA vs Not C-GCA

- 769 Table S11: Differential protein abundance analysis C-GCA TAB+ vs Not C-GCA
- 770 Table S12: Differential protein abundance analysis C-GCA TAB- vs Not C-GCA
- 771 Table S13: Characteristics of Not C-GCA cases and C-GCA patients stratified by TAB result
- 772 Table S14: Differential protein abundance analysis Active TAK vs HC
- Table S15: Differential protein abundance analysis Active LV-GCA vs HC
- Table S16: Comparison of active TAK, active LV-GCA and C-GCA TAB+ proteomic profiles
- 775 Table S17: Proteins & Genes dysregulated in both LVV plasma and arterial tissue
- 776 Note, Tables S2 and S13 are also provided in the supplementary information file for
- 777 convenience.

References 778

- 779 1. Pugh D, Karabayas M, Basu N, Cid MC, Goel R, Goodyear CS, et al. Large vessel 780 vasculitis. Nat Rev Dis Primer. 2022 Jan 6;7(1):93.
- 781 2. Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, 782 monitoring and management. Rheumatology. 2018 Feb 1;57(suppl 2):ii32-42.
- 783 3. Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, et al. Patterns 784 of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care Res. 785 2020;72(11):1615-24.
- 786 Grayson PC. Lumpers and Splitters: Ongoing Issues in the Classification of Large Vessel 4. 787 Vasculitis. J Rheumatol. 2015 Feb 1;42(2):149-51.
- 788 5. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell 789 arteritis: a spectrum within the same disease? Medicine (Baltimore). 2009 Jul;88(4):221-790 6.
- 791 Watanabe Y, Miyata T, Tanemoto K. Current Clinical Features of New Patients With 6. 792 Takayasu Arteritis Observed From Cross-Country Research in Japan. Circulation. 2015 793 Nov 3;132(18):1701–9.
- 794 7. Tombetti E, Hysa E, Mason JC, Cimmino MA, Camellino D. Blood Biomarkers for 795 Monitoring and Prognosis of Large Vessel Vasculitides. Curr Rheumatol Rep. 2021 Feb 796 10;23(3):17.
- 797 8. O'Connor TE, Carpenter HE, Bidari S, Waters MF, Hedna VS. Role of inflammatory 798 markers in Takayasu arteritis disease monitoring. BMC Neurol. 2014 Mar 28;14:62.
- 799 9. Broder MS, Sarsour K, Chang E, Collinson N, Tuckwell K, Napalkov P, et al. Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based 800 801 analysis. Semin Arthritis Rheum. 2016 Oct 1;46(2):246-52.
- 802 10. Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral 803 glucocorticoid cardiovascular risks in people with immune-mediated inflammatory 804 diseases: A population-based cohort study. PLOS Med. 2020 Dec 3;17(12):e1003432.
- 805 11. Joshi A, Rienks M, Theofilatos K, Mayr M. Systems biology in cardiovascular disease: a 806 multiomics approach. Nat Rev Cardiol. 2021 May;18(5):313-30.
- 807 12. Cui X, Qin F, Song L, Wang T, Geng B, Zhang W, et al. Novel Biomarkers for the 808 Precisive Diagnosis and Activity Classification of Takayasu Arteritis. Circ Genomic Precis 809 Med. 2019 Jan;12(1):e002080.
- 810 13. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of 811 Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017 Jul 27;377(4):317-28.
- 812 14. Robinette ML, Rao DA, Monach PA. The Immunopathology of Giant Cell Arteritis Across 813 Disease Spectra. Front Immunol [Internet]. 2021 Feb 25 [cited 2024 Jul 11];12. Available 814 from:
- 815 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.623716/fu 816 Ш

- 817 15. Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, et al.
 818 Development and initial validation of the Indian Takayasu Clinical Activity Score
 819 (ITAS2010). Rheumatol Oxf Engl. 2013 Oct;52(10):1795–801.
- Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, et al. The Role of
 Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of
 Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health
 Technol Assess Winch Engl. 2016 Nov;20(90):1–238.
- Burja B, Feichtinger J, Lakota K, Thallinger GG, Sodin-Semrl S, Kuret T, et al. Utility of
 serological biomarkers for giant cell arteritis in a large cohort of treatment-naïve patients.
 Clin Rheumatol. 2019 Feb 1;38(2):317–29.
- 18. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue
 Expression (GTEx) project. Nat Genet. 2013 Jun;45(6):580–5.
- 19. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissuebased map of the human proteome. Science. 2015 Jan 23;347(6220):1260419.
- 831 20. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING
 832 database in 2023: protein-protein association networks and functional enrichment
 833 analyses for any sequenced genome of interest. Nucleic Acids Res. 2023 Jan
 834 6;51(D1):D638–46.
- 835 21. Hur B, Koster MJ, Jang JS, Weyand CM, Warrington KJ, Sung J. Global Transcriptomic
 836 Profiling Identifies Differential Gene Expression Signatures between Inflammatory and
 837 Non-inflammatory Aortic Aneurysms. Arthritis Rheumatol Hoboken NJ. 2022
 838 Aug;74(8):1376–86.
- 839 22. Fernández JM, de la Torre V, Richardson D, Royo R, Puiggròs M, Moncunill V, et al. The
 840 BLUEPRINT Data Analysis Portal. Cell Syst. 2016 Nov 23;3(5):491-495.e5.
- 841 23. Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, et al. 2022
 842 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.
 843 Arthritis Rheumatol. 2022;74(12):1872–80.
- Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022
 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.
 Arthritis Rheumatol. 2022;74(12):1881–9.
- 25. Carmona FD, Coit P, Saruhan-Direskeneli G, Hernández-Rodríguez J, Cid MC, Solans
 R, et al. Analysis of the common genetic component of large-vessel vasculitides through
 a meta-Immunochip strategy. Sci Rep. 2017 Mar 9;7:43953.
- 850 26. Kong X, Xu M, Cui X, Ma L, Cheng H, Hou J, et al. Potential Role of Macrophage
 851 Phenotypes and CCL2 in the Pathogenesis of Takayasu Arteritis. Front Immunol. 2021
 852 May 17;12:646516.
- 27. Jiemy WF, van Sleen Y, van der Geest KS, ten Berge HA, Abdulahad WH, Sandovici M, et al. Distinct macrophage phenotypes skewed by local granulocyte macrophage colonystimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis. Clin Transl Immunol. 2020 Aug 27;9(9):e1164.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.06.24313218; this version posted September 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 858 28. Aloufi NA, Ali AK, Burke Schinkel SC, Molyer B, Barros PO, McBane JE, et al. Soluble CD127 potentiates IL-7 activity in vivo in healthy mice. Immun Inflamm Dis. 859 860 2021;9(4):1798-808.
- 861 29. Yoon T, Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW. Serum soluble interleukin-7 862 receptor alpha levels are negatively correlated with the simultaneous activity of 863 antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol. 2023 864 Apr;41(4):879-86.
- 865 30. Lundtoft C, Afum-Adjei Awuah A, Rimpler J, Harling K, Nausch N, Kohns M, et al. 866 Aberrant plasma IL-7 and soluble IL-7 receptor levels indicate impaired T-cell response 867 to IL-7 in human tuberculosis. PLoS Pathog. 2017 Jun 5;13(6):e1006425.
- 868 31. Meyer A, Parmar PJ, Shahrara S. Significance of IL-7 and IL-7R in RA and autoimmunity. 869 Autoimmun Rev. 2022 Jul 1;21(7):103120.
- 870 32. Ware CF, Croft M, Neil GA. Realigning the LIGHT signaling network to control 871 dysregulated inflammation. J Exp Med. 2022 May 23;219(7):e20220236.
- 872 33. Shaikh RB, Santee S, Granger SW, Butrovich K, Cheung T, Kronenberg M, et al. 873 Constitutive Expression of LIGHT on T Cells Leads to Lymphocyte Activation, 874 Inflammation, and Tissue Destruction. J Immunol. 2001 Dec 1;167(11):6330-7.
- 875 34. Herro R, Croft M. The control of tissue fibrosis by the inflammatory molecule LIGHT (TNF 876 Superfamily member 14). Pharmacol Res. 2016 Feb;104:151-5.
- 877 35. Golledge J, Clancy P, Maguire J, Lincz L, Koblar S. The role of tenascin C in 878 cardiovascular disease. Cardiovasc Res. 2011 Oct 1;92(1):19-28.
- 879 Berthoud TK, Dunachie SJ, Todryk S, Hill AVS, Fletcher HA. MIG (CXCL9) is a more 36. 880 sensitive measure than IFN-y of vaccine induced T-cell responses in volunteers receiving 881 investigated malaria vaccines. J Immunol Methods. 2009 Jan 1:340(1):33-41.
- 882 37. Graver JC, Abdulahad W, van der Geest KSM, Heeringa P, Boots AMH, Brouwer E, et 883 al. Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in 884 giant cell arteritis and polymyalgia rheumatica. J Autoimmun. 2021 Sep;123:102684.
- 885 38. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell 886 responses in giant cell arteritis. Circulation. 2010 Feb 23;121(7):906-15.
- 887 39. Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and 888 Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol Hoboken 889 NJ. 2015 May;67(5):1353-60.
- 890 40. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu 891 arteritis. Ann Intern Med. 1994 Jun 1;120(11):919-29.
- 892 Tasaki S, Suzuki K, Kassai Y, Takeshita M, Murota A, Kondo Y, et al. Multi-omics 41. 893 monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat 894 Commun. 2018 Jul 16;9:2755.
- 895 42. Koster MJ, Yeruva K, Crowson CS, Muratore F, Labarca C, Warrington KJ. Giant cell 896 arteritis and its mimics: A comparison of three patient cohorts. Semin Arthritis Rheum. 897 2020 Oct;50(5):923-9.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.06.24313218; this version posted September 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- 898 43. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: Clinical spectrum and predictive factors for positive 899 900 temporal artery biopsy. Semin Arthritis Rheum. 2001 Feb 1;30(4):249-56.
- 901 44. Duhaut P, Pinède L, Bornet H, Demolombe-Ragué S, Dumontet C, Ninet J, et al. Biopsy 902 proven and biopsy negative temporal arteritis: differences in clinical spectrum at the 903 onset of the disease. Ann Rheum Dis. 1999 Jun 1;58(6):335-41.
- 904 45. Chatelain D, Duhaut P, Schmidt J, Loire R, Bosshard S, Guernou M, et al. Pathological 905 features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis. 2009 Jan 1:68(1):84-8. 906
- 907 46. Putman MS, Gribbons KB, Ponte C, Robson J, Suppiah R, Craven A, et al. 908 Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell 909 Arteritis. Arthritis Care Res. 2022 Jun;74(6):1013-8.
- 910 47. Westreich D, Greenland S. The Table 2 Fallacy: Presenting and Interpreting Confounder 911 and Modifier Coefficients. Am J Epidemiol. 2013 Feb 15;177(4):292-8.
- 912 48. Schisterman EF, Cole SR, Platt RW. Overadjustment Bias and Unnecessary Adjustment 913 in Epidemiologic Studies. Epidemiol Camb Mass. 2009 Jul;20(4):488–95.
- 914 49. Csárdi G, Nepusz T. The igraph software package for complex network research. In 2006 915 [cited 2024 Jul 11]. Available from: https://www.semanticscholar.org/paper/The-igraph-916 software-package-for-complex-network-Cs%C3%A1rdi-917 Nepusz/1d2744b83519657f5f2610698a8ddd177ced4f5c
- 918 50. Chen Y, Lun ATL, Smyth GK. From reads to genes to pathways: differential expression 919 analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood 920 pipeline. F1000Research. 2016 Aug 2;5:1438.